Drug Trial Radar · NCT06612151
A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer (TAISHAN-302)
Last checked: Nov 19, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
438
Planned (sponsor's estimate)
Start
Dec 17, 2024
Primary completion
Dec 1, 2027
Study completion Dec 1, 2030
Sponsor
- Lead sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 25, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study was designed to compare the efficacy and safety of YL201 with Topotecan Hydrochloride in subjects with relapsed small cell lung cancer (SCLC).
Conditions
- Small Cell Lung Cancer
Interventions
YL201Drug
Patients will be treated with YL201 intravenous (IV) infusion once every 3 weeks (Q3W) as a cycle at RP3D dose level.
topotecan hydrochloride for injectionDrug
Topotecan hydrochloride will be administered intravenously per prescribing information.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To compare the OS of YL201 versus topotecan hydrochloride in subjects with relapsed SCLC.Time frame: Approximately within 36 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.